{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:48:52Z","timestamp":1786736932316,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/ijd.ijd_321_18","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T02:52:20Z","timestamp":1586832740000},"page":"214","source":"Crossref","is-referenced-by-count":8,"title":["Nivolumab-induced bullous pemphigoid managed without drug withdrawal"],"prefix":"10.4103","volume":"65","author":[{"given":"M\u00f3nica","family":"Munera-Campos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e0","family":"Plana-Pla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Ferr\u00e1ndiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-5154.282448-1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/CJI.0000000000000191","article-title":"Acute flare of bullous pemphigus with pembrolizumab used for treatment of metastatic urothelial cancer","author":"Garje","year":"2018","journal-title":"J Immunother"},{"key":"key-10.4103\/0019-5154.282448-2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/CJI.0000000000000210","article-title":"Bullous pemphigoid-like skin lesions and overt eosinophilia in a patient with melanoma treated with nivolumab: Case report and review of the literature","author":"Anastasopoulou","year":"2018","journal-title":"J Immunother"},{"key":"key-10.4103\/0019-5154.282448-3","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/1346-8138.14043","article-title":"Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab","author":"Kuwatsuka","year":"2018","journal-title":"J Dermatol"},{"key":"key-10.4103\/0019-5154.282448-4","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","article-title":"Development of bullous pemphigoid during nivolumab therapy","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"key":"key-10.4103\/0019-5154.282448-5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ced.13042","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"key-10.4103\/0019-5154.282448-6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"key-10.4103\/0019-5154.282448-7","first-page":"1758834017751634","article-title":"Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: Clinical features and management","author":"Shen","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"key-10.4103\/0019-5154.282448-8","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1111\/jdv.14143","article-title":"Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor","author":"Kwon","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0019-5154.282448-9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:47:59Z","timestamp":1786733279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_321_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"alternative-id":["282448"],"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_321_18","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}